Press releases
- PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results
- CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients
- PTC Therapeutics to Participate at Upcoming Investor Conference
- PTC Therapeutics Announces Validation of Sepiapterin European MAA
- PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
- PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
- PTC Therapeutics to Participate at Upcoming Investor Conferences
More ▼
Key statistics
On Friday, PTC Therapeutics Inc (BH3:MUN) closed at 31.00, -19.69% below its 52-week high of 38.60, set on Sep 11, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 31.00 |
---|---|
High | 31.00 |
Low | 31.00 |
Bid | 30.80 |
Offer | 31.60 |
Previous close | 31.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 76.70m |
Free float | 74.88m |
P/E (TTM) | -- |
Market cap | 2.61bn USD |
EPS (TTM) | -7.69 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 07:02 BST.
More ▼